Mednet Logo
Community

Assuming a clinical trial is unavailable, would you consider tazemetostat in a patient with metastatic INI1/SMARCB1 deficient sinonasal carcinoma?

Has anyone tried this approach with success?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Virginia
Answered on

I would certainly consider Tazmetostat for INI deficient SNUC, if progressed on front-line therapy and no trials available.

Join for free or sign in to see the full answer